Rite Aid Pharmacy 03510 Durable Medical Equipment & Medical Supplies Location: 337 N State Rd, Otisville, Michigan 48463 Phone: (810) 631-4551 |
News Archive
Physicians at Rush University Medical Center are offering a new and effective treatment to patients suffering from complex brain aneurysms. The recently FDA-approved technology called the Pipeline Embolization Device (PED) gives doctors the ability for the very first time to treat some of the most complex and dangerous brain aneurysms using minimally invasive techniques.
Revolutions Medical Corporation is happy to report that it has received notice that Investigational Review Board approval has been granted this month to the Philadelphia College of Osteopathic Medicine for the research project application titled 'Characterization of Intracranial Hemorrhages by Color MRI Automatic Segmentation,' by Dr. H. Keith Brown and his collaborators.
Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.
Leading medical experts today [Thursday 27 November] warn that rising numbers of deaths from liver disease - already the UK's third commonest cause of premature death - will be unavoidable without radical improvements in treatment and detection services, and tougher government policies to control the excessive alcohol use and obesity responsible for much of the national burden of liver disease.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
› Verified 1 days ago